Bone Marrow Monocytes and Derived Dendritic Cells from Myelodysplastic Patients Have Functional Abnormalities Associated with Defective Response to Bacterial Infection.
Laiz C BentoNydia S BacalFernanda A RochaPatricia SeverinoLuciana Cavalheiro MartiPublished in: Journal of immunology (Baltimore, Md. : 1950) (2020)
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell diseases characterized by dysplasia of one or more hematologic lineages and a high risk of developing into acute myeloid leukemia. MDS patients have recurrent bacterial infections and abnormal expression of CD56 by monocytes. We investigated MDS patients' bone marrow CD56+/CD56- monocytes and their in vitro-derived dendritic cell populations in comparison with cells obtained from disease-free subjects. We found that monocytes from MDS patients, irrespective of CD56 expression, have reduced phagocytosis activity and low expression of genes involved in triggering immune responses, regulation of immune and inflammatory response signaling pathways, and in the response to LPS. Dendritic cells derived in vitro from MDS monocytes failed to develop dendritic projections and had reduced expression of HLA-DR and CD86, suggesting that Ag processing and T cell activation capabilities are impaired. In conclusion, we identified, in both CD56+ and CD56- monocytes from MDS patients, several abnormalities that may be related to the increased susceptibility to infections observed in these patients.
Keyphrases
- dendritic cells
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- bone marrow
- acute myeloid leukemia
- immune response
- peritoneal dialysis
- prognostic factors
- mesenchymal stem cells
- cell proliferation
- high resolution
- oxidative stress
- cell death
- regulatory t cells
- quantum dots
- endoplasmic reticulum stress